![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Lloyds Bk. 31 | LSE:93CZ | London | Medium Term Loan |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0 | - |
RNS No 949c OXFORD BIOMEDICA PLC 26th January 1998 For further information contact: Oxford BioMedica plc Professor Alan Kingsman, Chief Executive Officer Tel: 01865 783 000 Trade/Scientific Press Enquiries HCC De Facto Consultants, Michaela Mahon Tel: 01256 842 274 City/Financial Press Enquiries HCC De Facto Financial, Nicola How Tel: 0171 957 4600 OXFORD BIOMEDICA ANNOUNCES INTERACTION WITH RHONE-POULENC RORER Agreement is signed with leading pharmaceutical company Oxford UK, 26th January 1998. Oxford BioMedica plc announced today that it has signed an agreement with Rhone-Poulenc Rorer, a wholly-owned subsidiary of Rhone-Poulenc S.A. (NYSE.RP), to undertake a collaborative research feasibility study. The research will investigate the use of Oxford BioMedica's novel lentiviral vector systems in Rhone-Poulenc Rorer's functional genomics programme. Rhone-Poulenc Rorer will exploit the ability of this new generation of vectors to transfer genes to certain non-dividing tissues. Professor Alan Kingsman, Oxford BioMedica's Chief Executive, commented: "We are delighted that Rhone-Poulenc Rorer has chosen to evaluate our new vectors for its genomics programme. We believe this is a powerful endorsement of Oxford BioMedica's technical strength and emphasises the importance of our new gene delivery systems." Dr Neill MacKenzie, Business Development Director, added: "This deal adds weight to our belief that the lentiviral vector technology has enormous commercial potential. Rhone-Poulenc Rorer is the first company to gain access to these vectors from Oxford BioMedica. We are in discussion with several other companies in relation to this technology." Notes to Editors: 1. Oxford BioMedica, established in 1995, specialises in the development and application of gene-based therapeutics using advanced retroviral gene delivery technologies for the treatment of disease in the areas of: oncology, viral infection, neurobiology and genetic deficiency. Oxford BioMedica plc was floated on the UK Alternative Investment Market of the London Stock Exchange in December 1996. 2. Rhone-Poulenc Rorer is a global pharmaceutical company dedicated to improving human health. END MSCBRGBBSXDCCIX
1 Year Lloyds Bk. 31 Chart |
1 Month Lloyds Bk. 31 Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions